Novartis Petitions Patent Board Over Compositions Used In Gene Therapy

(February 24, 2023, 9:40 AM EST) -- ALEXANDRIA, Va. — A Genzyme Corp. patent directed to compositions for improving the storage stability of recombinant virus particles for use in gene therapy should be canceled as obvious to a person of skill in the art (POSA), a petition for inter partes review (IPR) asserts....

Attached Documents

Related Sections